Edition:
United Kingdom

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

96.45EUR
10:33am BST
Change (% chg)

€-1.05 (-1.08%)
Prev Close
€97.50
Open
€97.25
Day's High
€97.50
Day's Low
€96.00
Volume
14,075
Avg. Vol
104,673
52-wk High
€99.20
52-wk Low
€68.60

Latest Key Developments (Source: Significant Developments)

Diasorin SpA Q1 Net Profit Up At EUR 40.4 Mln
Thursday, 9 May 2019 

May 9 (Reuters) - DiaSorin SpA ::Q1 REVENUE EUR 170.8 MILLION VERSUS EUR 164.5 MILLION YEAR AGO.Q1 NET PROFIT EUR 40.4 MILLION VERSUS EUR 38.3 MILLION YEAR AGO.  Full Article

Diasorin Gets Authorization For Marketing OF Vitamin B12 And Folate Quantification Tests In Europe
Wednesday, 3 Apr 2019 

April 3 (Reuters) - DiaSorin SpA ::GETS AUTHORIZATION FOR MARKETING IN EUROPE OF TESTS FOR QUANTIFICATION OF VITAMIN B12 AND FOLATE TO SUPPORT DIAGNOSIS AND TREATMENT OF ANEMIA.  Full Article

DiaSorin Proposes Ordinary Dividend Of EUR 0.90 /shr
Thursday, 14 Mar 2019 

March 14 (Reuters) - DiaSorin SpA ::PROPOSED ORDINARY DIVIDEND OF EUR 0.90 PER SHARE.  Full Article

DiaSorin FY Net Profit Up At EUR 158.1 Mln
Thursday, 14 Mar 2019 

March 14 (Reuters) - DiaSorin SpA ::FY NET PROFIT EUR 158.1 MILLION, UP 13.0% VERSUS YEAR AGO.FY REVENUES: € 669.2 MILLION, +5.0% (+7.7% AT CER).2019 GUIDANCE AT CONSTANT EXCHANGE RATE FOR EBITDA MARGIN: COMPARABLE TO 2018 EBITDA MARGIN RESULT.SEES REVENUES GROWTH BETWEEN 5.0% AND 8.0% IN 2019 AT CONSTANT EXCHANGE RATES.CAPITAL MARKET DAY: ON JUNE 11, 2019 IN TURIN.  Full Article

DiaSorin Launches 3 New Primer Pairs For Use In Molecular Testing Of Lung Infection
Friday, 21 Dec 2018 

Dec 21 (Reuters) - DiaSorin SpA ::LAUNCHES 3 NEW PRIMER PAIRS FOR USE IN MOLECULAR TESTING.SPECIFIC TARGETS ARE LEGIONELLA SPECIES, CHLAMYDOPHILA PNEUMONIAE AND MYCOPLASMA PNEUMONIAE.ALL THREE TEST TARGETS MAY INFECT LUNGS.  Full Article

Diasorin Shares Included In FTSE MIB Index As Of Dec 4
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - DiaSorin SpA ::ANNOUNCES THAT ITS SHARES ARE INCLUDED IN THE FTSE MIB INDEX OF MILAN STOCK EXCHANGE AS OF DEC 4.  Full Article

Diasorin And Meridian Enter Strategic Pact To Sell Stool Antigen Test In U.S. And UK
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Meridian Bioscience Inc ::PRESS RELEASE - DIASORIN AND MERIDIAN ENTER INTO A STRATEGIC COLLABORATION TO SELL HELICOBACTER PYLORI STOOL ANTIGEN TEST IN THE UNITED STATES AND IN THE UNITED KINGDOM.MERIDIAN BIOSCIENCE INC - MERIDIAN AND DIASORIN WILL BEGIN COLLABORATING ON SALES AND MARKETING EFFORTS TO HOSPITALS AND REFERENCE LABORATORIES IN U.S.MERIDIAN BIOSCIENCE - COLLABORATION TO RESULT IN TERMINATION OF PENDING LEGAL DISPUTES AND WILL EXPAND SCOPE OF AGREEMENT BETWEEN DIASORIN AND MERIDIAN.MERIDIAN BIOSCIENCE INC - MERIDIAN WILL RECEIVE ROYALTIES ON SALES OF LIAISON H. PYLORI STOOL ANTIGEN TEST IN U.S. AND NOW ALSO IN UK.MERIDIAN BIOSCIENCE - MERIDIAN AND DIASORIN HAVE OUTLINED A FRAMEWORK WHERE THEY MAY PARTNER TO DEVELOP OTHER STOOL-BASED TESTS FOR USE ON LIAISON PLATFORM.  Full Article

Diasorin And Meridian Enter Into A Strategic Collaboration
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Diasorin Spa ::SAYS DIASORIN AND MERIDIAN ENTER INTO A STRATEGIC COLLABORATION TO SELL HELICOBACTER PYLORI STOOL ANTIGEN TEST IN U.S. AND IN U.K.MERIDIAN AND DIASORIN WILL BEGIN COLLABORATING ON SALES AND MARKETING EFFORTS TO HOSPITALS AND REFERENCE LABORATORIES IN U.S..MERIDIAN WILL RECEIVE ROYALTIES ON SALES OF LIAISON H. PYLORI STOOL ANTIGEN TEST IN U.S. AND ALSO IN UK.MERIDIAN AND DIASORIN HAVE OUTLINED A FRAMEWORK WHERE THEY MAY PARTNER TO DEVELOP OTHER STOOL-BASED TESTS FOR USE ON LIAISON PLATFORM.  Full Article

Diasorin Q2 Net Profit Up At EUR 42.5 Mln
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - DiaSorin SpA ::Q2 REVENUE EUR 166.7 MILLION VERSUS EUR 161.8 MILLION YEAR AGO.Q2 NET PROFIT EUR 42.5 MILLION VERSUS EUR 33.6 MILLION YEAR AGO.UPDATES 2018 GUIDANCE.SEES 2018 REVENUE GROWTH EQUAL TO AROUND +9% AT CONSTANT CURRENCIES VERSUS 2017 (PREVIOUS GUIDANCE: AROUND +11%).SEES 2018 EBITDA GROWTH AROUND +12% AT CONSTANT CURRENCIES VERSUS 2017 (PREVIOUS GUIDANCE: AROUND +13%).  Full Article

Diasorin Launches Hepatitis Delta (HDV) Test On Liaison XL Platform
Friday, 27 Jul 2018 

July 27 (Reuters) - DiaSorin SpA ::LAUNCHES THE TEST FOR THE DETECTION OF THE HEPATITIS DELTA (HDV) ON LIAISON XL IN EUROPE.  Full Article

DIARY - Italy to June 30

Inclusion of diary items does not necessarily mean that Reuters will file a story based on the event.